Dr. Daniel Weiner Joins Simulations Plus Board of Directors
May 01 2017 - 8:30AM
Business Wire
World-renowned scientist, FDA consultant,
and experienced manager to reinforce SLP board
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of
simulation and modeling software for pharmaceutical discovery and
development, today announced that Dr. Daniel Weiner, an expert on
pharmacokinetic modeling and pharmacodynamics, has become a member
of its Board of Directors effective today, filling the vacancy
created when Dr. David D’Argenio retired from the board last
year.
Walt Woltosz, chairman and chief executive officer of
Simulations Plus, said: “We’re excited to announce that Dr. Daniel
Weiner has become a member of the Simulations Plus Board of
Directors effective today. Dr. Weiner brings decades of directly
relevant experience in pharmaceutical software development and is
world renowned for his work in pharmacokinetics and
pharmacodynamics.”
Dr. Weiner has extensive drug development experience and has
served as an expert consultant to the U.S. Food and Drug
Administration (FDA) on pharmacokinetic modeling and bioequivalence
assessment. Prior to his previous tenure with Certara/Pharsight as
a Senior Vice President and Chief Science Officer, Dr. Weiner held
several management positions with Merrell Dow Pharmaceuticals;
Statistical Consultants, Inc.; Syntex Development Research;
Quintiles; and IVAX Research. Dr. Weiner graduated from the
University of Kentucky with a doctoral degree in Mathematical
Statistics, with emphasis on compartmental modeling. He is the
original designer/author of the WinNonlin family of PK/PD Modeling
Software now used by over 1,000 institutions. He is the co-author
of Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and
Applications, now in its fifth edition. Dr. Weiner is an Adjunct
Associate Professor with the Division of Pharmacotherapy and
Experimental Therapeutics in the School of Pharmacy, University of
North Carolina, and an Affiliate Professor of Pharmacometrics,
Center for Translational Medicine in the School of Pharmacy at the
University of Maryland.
Regarding his new appointment, Dr. Weiner stated: “Simulations
Plus is a leader in the development of software products and
providing consulting services that utilize quantitative systems
pharmacology (QSP) to support model-based drug development (MBDD),
concepts for which I am a passionate advocate. I have been very
impressed with the quality of the science and scientists at
Simulations Plus, and the solid corporation that Walt and his team
have built. I am both honored and pleased to accept a position on
the Board of Directors, and look forward to assisting the company
in its endeavors.”
About Simulations Plus, Inc.
Simulations Plus, Inc. is a premier developer of drug discovery
and development software as well as a leading provider of both
preclinical and clinical pharmacometric consulting services for
regulatory submissions. The company is a global leader focused on
improving the ways scientists use knowledge and data to predict the
properties and outcomes of pharmaceutical and biotechnology agents.
Our software is licensed to and used in the conduct of drug
research by major pharmaceutical and biotechnology companies and
regulatory agencies worldwide. Our innovations in integrating new
and existing science in medicinal chemistry, computational
chemistry, pharmaceutical science, biology, and physiology into our
software have made us the leading software provider for
physiologically based pharmacokinetic modeling and simulation. For
more information, visit our website at
www.simulations-plus.com.
Follow us on Twitter | LinkedIn
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170501005351/en/
Simulations Plus Investor
RelationsMs. Renée
Bouché661-723-7723renee@simulations-plus.comorHayden IRMr. Cameron
Donahue651-653-1854cameron@haydenir.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Apr 2023 to Apr 2024